Business Wire

Merz Aesthetics Announces the Launch of Ultherapy PRIME Platform as the Next Generation of Nonsurgical Skin Lifting Treatments

23.9.2024 14:00:00 CEST | Business Wire | Press Release

Share

Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the launch of Ultherapy PRIME – a noninvasive treatment that provides a truly personalized and long-lasting* lift of the skin in one session with zero downtime.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240923820281/en/

Merz Aesthetics Announces the Launch of Ultherapy PRIME Platform as the Next Generation of Nonsurgical Skin Lifting Treatments (Photo: Business Wire)

The Ultherapy PRIME platform is the evolution of Ultherapy®, which has been recognized as the Gold Standard for nonsurgical lifting and skin tightening due to its large body of clinical evidence, well-established mechanism of action (MOA) and high patient satisfaction.1,2,3 Built on a legacy of proven, natural-looking outcomes, Ultherapy PRIME redefines the future of non-invasive skin lifting and tightening by uniquely combining advanced ultrasound technology, vivid real-time imaging and proven results. These advancements promote long-lasting* results paired with healthier-looking skin.1,2,3,4,5

The platform features a modern design with an advanced operating system, delivering 10x faster processing power, elevated ergonomics and seamless workflows for aesthetic health care professionals. Additionally, with a 35% larger screen and brighter, crisp images from all angles, Ultherapy PRIME offers a vivid visualization experience for a truly personalized, long-lasting* lift patients can see.**

“The launch of Ultherapy PRIME demonstrates our commitment to persist in innovation,” said Bob Rhatigan, CEO, Merz Aesthetics. “As the leader in noninvasive lifting, we’re excited to bring Ultherapy PRIME to our customers as the next generation, premier platform and as a proven technology*** and customizable, long-lasting* treatment option.”

Ultherapy PRIME’s unique technology with real-time visualization goes beyond other noninvasive treatments to target the right collagen and elastin-rich layers of the tissue at multiple depths, delivering consistent and precise energy where the patient needs it the most.1,2,3,4,6,7 Ultherapy PRIME’s mechanism of action allows for personalized skin lifting outcomes through collagen and elastin stimulation, which can last up to a year or more.1,2,3,4,6,7 It is a great treatment option for all skin types and skin tones to maintain a youthful, healthy appearance in just one session with zero downtime.1

With three million Ultherapy treatments performed around the world, Ultherapy PRIME builds on an impressive legacy of lifts of the skin on the brows, area under the chin and neck and improves lines and wrinkles on the décolleté.1,2,3 With Ultherapy’s 95% patient satisfaction at year one and one of the strongest clinical bodies of evidence cited in over 120 publications and 56 clinical studies,2,4 Ultherapy PRIME is built on a legacy of safe and effective treatments. Ultherapy PRIME is The Lift You Can SEE.

“Now more than ever, patients seek treatments tailored to their unique skin needs. This is why Ultherapy is a cornerstone of my practice,” said world-renowned, board-certified dermatologist Sabrina Fabi, MD. “The new Ultherapy PRIME platform offers all the signature benefits of Ultherapy for noninvasive, long-lasting* lifting, now with significant advancements. Ultherapy PRIME improves the quality of the skin, catering to diverse patient needs with all skin types seeking a noninvasive lift and a younger, healthier appearance in just one session and no downtime.”

To learn more about Ultherapy PRIME, visit Ultherapy.com and follow @Ultherapy on Instagram.

*results can last up to a year or more 1,4
** in comparison to the previous version
***based on clinical studies conducted with Ultherapy legacy device

About Merz Aesthetics

Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.

About Ultherapy®:

The noninvasive Ultherapy® procedure is intended for dermatological sculpting and lifting of the dermis on the upper face, lower face, neck and décolleté. The most common side effects reported in clinical trials were redness, swelling, pain and transient nerve effects. Reported adverse events from post-marketing surveillance are available in the Instructions for Use (IFU). Please see the IFU for product information.

References:

  1. Ulthera® Instructions for Use
  2. Fabi SG, Joseph J, Sevi J, Green JB, Peterson JD. Optimizing patient outcomes by customizing treatment with microfocused ultrasound with visualization: gold standard consensus guidelines from an expert panel. J Drugs Dermatol. 2019;18(5):426-432.
  3. Park JY, et al. Customized Treatment Using Microfocused Ultrasound with Visualization for Optimized Patient Outcomes: A Review of Skin tightening Energy Technologies and a Pan-Asian Adaptation of the Expert Panel’s Gold Standard Consensus. J Clin Aesthet Dermatol. 2021;14(5): E70-E79.
  4. Werschler WP, Werschler PS. Long-term efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;9(2):27-33.
  5. Goldie K, Kerscher M, Fabi SG, Hirano C, Landau M, Lim TS, Woolery-Lloyd H, Mariwalla K, Park JY, Yutskovskaya Y. Skin Quality - A Holistic 360° View: Consensus Results. Clin Cosmet Investig Dermatol. 2021 Jun 14;14:643-654. doi: 10.2147/CCID.S309374. PMID: 34163203; PMCID: PMC8214518.
  6. Sasaki G, Grossman J, Fabi SG, et al. Stimulation of Collagen Synthesis in Human Skin Following Microfocused Ultrasound Therapy. Presented at the ASDS 2018 Annual Meeting.
  7. White WM, Makin IR, Barthe PG, Slayton MN, Gliklich RE. Selective creation of thermal injury zones in the superficial musculoaponeurotic system using intense ultrasound therapy: a new target for non-invasive facial rejuvenation. Arch Facial Plast Surg. 2007;9(1):22-29.

© 2024 Merz North America, Inc., Merz, and Merz Aesthetics are trademarks or registered trademarks of Merz Pharma GmbH & Co. KGaA in the EU and/or certain other countries. Ultherapy, Ulthera are trademarks and/or registered trademarks of Ulthera, Inc. in the EU and/or certain other countries. Various features of the ULTHERA® System are covered by U.S. patents identified at https://merzaesthetics.com/patents/. Other U.S. and International patents to which Ulthera, Inc. has rights are issued, published, or pending.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240923820281/en/

Contacts

Emily Browder
Head of Global Communications
6501 Six Forks Road Raleigh NC 27615
919-302-3296
media@merz.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

South African Agency Boundless Delivers Mazda’s First AI-produced Commercial Using Luma Agents15.4.2026 21:07:00 CEST | Press Release

Luma AI today announced that Boundless, an independent creative agency based in Johannesburg, South Africa, has produced Mazda’s first AI-produced commercial using Luma Agents, Luma’s AI-powered creative workflow system. Delivered in less than two weeks from initial brief to final approval, the project marks a significant step in the use of AI-native workflows for commercial production. As part of the collaboration, Boundless has also signed an agreement with Luma to integrate the company’s AI technologies into its creative workflow across future client work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415098939/en/ The project marks a milestone for both Boundless and the broader advertising industry, demonstrating how AI-native workflows can help agencies compress production timelines while maintaining creative quality, brand consistency, and operational oversight. The campaign supports the re-entry of the Mazda MX-5

Chaired by HRH Crown Prince, PIF Board of Directors Approves PIF 2026-2030 Strategy15.4.2026 17:29:00 CEST | Press Release

The Board of Directors ofPIF, chaired by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince, Prime Minister and Chairman of the Board of Directors of PIF, has approved PIF’s 2026-2030 strategy, which is a continuation of PIF’s long-term strategy. The strategy will focus on delivering competitive domestic ecosystems to connect sectors, unlock the full potential of strategic assets, maximize long-term returns, and continue to drive the economic transformation of Saudi Arabia and further enhance the quality of life of its citizens. The 2026-2030 strategy marks a natural evolution as PIF moves from a period of rapid growth and acceleration to a new phase of sustained value creation, with a strengthened focus on maximizing impact, raising the efficiency of investments, and applying the highest standards of governance, transparency and institutional excellence. In addition, PIF will further enable the role of the private sector as an effective partner for susta

Chaired by HRH Crown Prince, PIF Board of Directors Approves PIF 2026-2030 Strategy15.4.2026 17:29:00 CEST | Press Release

The Board of Directors ofPIF, chaired by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince, Prime Minister and Chairman of the Board of Directors of PIF, has approved PIF’s 2026-2030 strategy, which is a continuation of PIF’s long-term strategy. The strategy will focus on delivering competitive domestic ecosystems to connect sectors, unlock the full potential of strategic assets, maximize long-term returns, and continue to drive the economic transformation of Saudi Arabia and further enhance the quality of life of its citizens. The 2026-2030 strategy marks a natural evolution as PIF moves from a period of rapid growth and acceleration to a new phase of sustained value creation, with a strengthened focus on maximizing impact, raising the efficiency of investments, and applying the highest standards of governance, transparency and institutional excellence. In addition, PIF will further enable the role of the private sector as an effective partner for susta

New Method Enables Structural Determination of Diverse Phenolic Compounds from a Tiny Alpine Flower Sample15.4.2026 16:00:00 CEST | Press Release

Hyuga Hirano (United Graduate School of Agricultural Science, Tokyo University of Agriculture and Technology, and collaborative graduate student at the National Museum of Nature and Science (President: Makoto Manabe)); Takashi Kikuchi (Application Laboratories, Global Product Unit, Rigaku Corporation, a group company of Rigaku Holdings); Futa Sakakibara (Technical Advisor, R&D Support Division, Asterism G.K.); Yoshinori Murai (Senior curator, Department of Botany, National Museum of Nature and Science); and colleagues have successfully determined the structures of more than ten phenolic glycosides from a tiny sample of an alpine plant flower by developing a trace analysis method. This achievement is particularly significant because alpine plants are typically small and difficult to collect due to legal, ethical, and environmental considerations, resulting in extremely limited sample availability. Determining the structures of numerous chemical components from such a small sample repres

New Method Enables Structural Determination of Diverse Phenolic Compounds from a Tiny Alpine Flower Sample15.4.2026 16:00:00 CEST | Press Release

Hyuga Hirano (United Graduate School of Agricultural Science, Tokyo University of Agriculture and Technology, and collaborative graduate student at the National Museum of Nature and Science (President: Makoto Manabe)); Takashi Kikuchi (Application Laboratories, Global Product Unit, Rigaku Corporation, a group company of Rigaku Holdings); Futa Sakakibara (Technical Advisor, R&D Support Division, Asterism G.K.); Yoshinori Murai (Senior curator, Department of Botany, National Museum of Nature and Science); and colleagues have successfully determined the structures of more than ten phenolic glycosides from a tiny sample of an alpine plant flower by developing a trace analysis method. This achievement is particularly significant because alpine plants are typically small and difficult to collect due to legal, ethical, and environmental considerations, resulting in extremely limited sample availability. Determining the structures of numerous chemical components from such a small sample repres

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye